 | • レポートコード：MRC23Q36199 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（2-3日） • 産業分類：化学＆材料 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のナノ医療/ナノバイオテクノロジー市場について調査・分析し、世界のナノ医療/ナノバイオテクノロジー市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（ナノ粒子、ナノシェル、ナノチューブ、ナノデバイス、その他）、用途別セグメント分析（病院、クリニック、研究所）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Abbott、GE Healthcare、Johnson & Johnson、Merck、Pfizer、CombiMatrix、Celgene、Mallinckrodt、Sigma-Tau Pharmaceuticals、Teva Pharmaceutical、Nanosphere、UCB SAなどが含まれています。 世界のナノ医療/ナノバイオテクノロジー市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、ナノ医療/ナノバイオテクノロジー市場規模を推定する際に考慮しました。本レポートは、ナノ医療/ナノバイオテクノロジーの世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、ナノ医療/ナノバイオテクノロジーに関するビジネス上の意思決定に役立てることを目的としています。 ・ナノ医療/ナノバイオテクノロジー市場の概要 - ナノ医療/ナノバイオテクノロジーのタイプ別セグメント - 世界のナノ医療/ナノバイオテクノロジー市場規模：タイプ別分析（ナノ粒子、ナノシェル、ナノチューブ、ナノデバイス、その他） - ナノ医療/ナノバイオテクノロジーの用途別セグメント - 世界のナノ医療/ナノバイオテクノロジー市場規模：用途別分析（病院、クリニック、研究所） - 世界のナノ医療/ナノバイオテクノロジー市場規模予測（2018年-2029年） ・ナノ医療/ナノバイオテクノロジー市場の成長トレンド - ナノ医療/ナノバイオテクノロジーの地域別市場規模（2018年-2029年） - ナノ医療/ナノバイオテクノロジー市場ダイナミクス - ナノ医療/ナノバイオテクノロジーの業界動向 - ナノ医療/ナノバイオテクノロジー市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：ナノ粒子、ナノシェル、ナノチューブ、ナノデバイス、その他 - 世界のナノ医療/ナノバイオテクノロジーのタイプ別市場規模（2018年-2023年） - 世界のナノ医療/ナノバイオテクノロジーのタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、クリニック、研究所 - 世界のナノ医療/ナノバイオテクノロジーの用途別市場規模（2018年-2023年） - 世界のナノ医療/ナノバイオテクノロジーの用途別市場規模（2024年-2029年） ・ナノ医療/ナノバイオテクノロジーの地域別市場規模 - 北米のナノ医療/ナノバイオテクノロジー市場規模（2018年-2029年） - アメリカのナノ医療/ナノバイオテクノロジー市場規模（2018年-2029年） - ヨーロッパのナノ医療/ナノバイオテクノロジー市場規模（2018年-2029年） - アジア太平洋のナノ医療/ナノバイオテクノロジー市場規模（2018年-2029年） - 中国のナノ医療/ナノバイオテクノロジー市場規模（2018年-2029年） - 日本のナノ医療/ナノバイオテクノロジー市場規模（2018年-2029年） - 韓国のナノ医療/ナノバイオテクノロジー市場規模（2018年-2029年） - インドのナノ医療/ナノバイオテクノロジー市場規模（2018年-2029年） - オーストラリアのナノ医療/ナノバイオテクノロジー市場規模（2018年-2029年） - 中南米のナノ医療/ナノバイオテクノロジー市場規模（2018年-2029年） - 中東・アフリカのナノ医療/ナノバイオテクノロジー市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Abbott、GE Healthcare、Johnson & Johnson、Merck、Pfizer、CombiMatrix、Celgene、Mallinckrodt、Sigma-Tau Pharmaceuticals、Teva Pharmaceutical、Nanosphere、UCB SA ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Nanomedicine and Nanobiotechnology market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Nanomedicine and Nanobiotechnology is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Nanomedicine and Nanobiotechnology is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Nanomedicine and Nanobiotechnology in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Nanomedicine and Nanobiotechnology include Abbott, GE Healthcare, Johnson & Johnson, Merck, Pfizer, CombiMatrix, Celgene, Mallinckrodt and Sigma-Tau Pharmaceuticals, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nanomedicine and Nanobiotechnology, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nanomedicine and Nanobiotechnology.
The Nanomedicine and Nanobiotechnology market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Nanomedicine and Nanobiotechnology market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nanomedicine and Nanobiotechnology companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Abbott
GE Healthcare
Johnson & Johnson
Merck
Pfizer
CombiMatrix
Celgene
Mallinckrodt
Sigma-Tau Pharmaceuticals
Teva Pharmaceutical
Nanosphere
UCB SA
Segment by Type
Nanoparticles
Nanoshells
Nanotubes
Nanodevices
Others
Segment by Application
Hospitals
Clinics
Research Institute
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nanomedicine and Nanobiotechnology companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nanomedicine and Nanobiotechnology Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Nanoparticles
1.2.3 Nanoshells
1.2.4 Nanotubes
1.2.5 Nanodevices
1.2.6 Others
1.3 Market by Application
1.3.1 Global Nanomedicine and Nanobiotechnology Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Research Institute
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nanomedicine and Nanobiotechnology Market Perspective (2018-2029)
2.2 Nanomedicine and Nanobiotechnology Growth Trends by Region
2.2.1 Global Nanomedicine and Nanobiotechnology Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Nanomedicine and Nanobiotechnology Historic Market Size by Region (2018-2023)
2.2.3 Nanomedicine and Nanobiotechnology Forecasted Market Size by Region (2024-2029)
2.3 Nanomedicine and Nanobiotechnology Market Dynamics
2.3.1 Nanomedicine and Nanobiotechnology Industry Trends
2.3.2 Nanomedicine and Nanobiotechnology Market Drivers
2.3.3 Nanomedicine and Nanobiotechnology Market Challenges
2.3.4 Nanomedicine and Nanobiotechnology Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nanomedicine and Nanobiotechnology Players by Revenue
3.1.1 Global Top Nanomedicine and Nanobiotechnology Players by Revenue (2018-2023)
3.1.2 Global Nanomedicine and Nanobiotechnology Revenue Market Share by Players (2018-2023)
3.2 Global Nanomedicine and Nanobiotechnology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nanomedicine and Nanobiotechnology Revenue
3.4 Global Nanomedicine and Nanobiotechnology Market Concentration Ratio
3.4.1 Global Nanomedicine and Nanobiotechnology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nanomedicine and Nanobiotechnology Revenue in 2022
3.5 Nanomedicine and Nanobiotechnology Key Players Head office and Area Served
3.6 Key Players Nanomedicine and Nanobiotechnology Product Solution and Service
3.7 Date of Enter into Nanomedicine and Nanobiotechnology Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Nanomedicine and Nanobiotechnology Breakdown Data by Type
4.1 Global Nanomedicine and Nanobiotechnology Historic Market Size by Type (2018-2023)
4.2 Global Nanomedicine and Nanobiotechnology Forecasted Market Size by Type (2024-2029)
5 Nanomedicine and Nanobiotechnology Breakdown Data by Application
5.1 Global Nanomedicine and Nanobiotechnology Historic Market Size by Application (2018-2023)
5.2 Global Nanomedicine and Nanobiotechnology Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Nanomedicine and Nanobiotechnology Market Size (2018-2029)
6.2 North America Nanomedicine and Nanobiotechnology Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Nanomedicine and Nanobiotechnology Market Size by Country (2018-2023)
6.4 North America Nanomedicine and Nanobiotechnology Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nanomedicine and Nanobiotechnology Market Size (2018-2029)
7.2 Europe Nanomedicine and Nanobiotechnology Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Nanomedicine and Nanobiotechnology Market Size by Country (2018-2023)
7.4 Europe Nanomedicine and Nanobiotechnology Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nanomedicine and Nanobiotechnology Market Size (2018-2029)
8.2 Asia-Pacific Nanomedicine and Nanobiotechnology Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Nanomedicine and Nanobiotechnology Market Size by Region (2018-2023)
8.4 Asia-Pacific Nanomedicine and Nanobiotechnology Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nanomedicine and Nanobiotechnology Market Size (2018-2029)
9.2 Latin America Nanomedicine and Nanobiotechnology Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Nanomedicine and Nanobiotechnology Market Size by Country (2018-2023)
9.4 Latin America Nanomedicine and Nanobiotechnology Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nanomedicine and Nanobiotechnology Market Size (2018-2029)
10.2 Middle East & Africa Nanomedicine and Nanobiotechnology Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Nanomedicine and Nanobiotechnology Market Size by Country (2018-2023)
10.4 Middle East & Africa Nanomedicine and Nanobiotechnology Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Detail
11.1.2 Abbott Business Overview
11.1.3 Abbott Nanomedicine and Nanobiotechnology Introduction
11.1.4 Abbott Revenue in Nanomedicine and Nanobiotechnology Business (2018-2023)
11.1.5 Abbott Recent Development
11.2 GE Healthcare
11.2.1 GE Healthcare Company Detail
11.2.2 GE Healthcare Business Overview
11.2.3 GE Healthcare Nanomedicine and Nanobiotechnology Introduction
11.2.4 GE Healthcare Revenue in Nanomedicine and Nanobiotechnology Business (2018-2023)
11.2.5 GE Healthcare Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Detail
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Nanomedicine and Nanobiotechnology Introduction
11.3.4 Johnson & Johnson Revenue in Nanomedicine and Nanobiotechnology Business (2018-2023)
11.3.5 Johnson & Johnson Recent Development
11.4 Merck
11.4.1 Merck Company Detail
11.4.2 Merck Business Overview
11.4.3 Merck Nanomedicine and Nanobiotechnology Introduction
11.4.4 Merck Revenue in Nanomedicine and Nanobiotechnology Business (2018-2023)
11.4.5 Merck Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Nanomedicine and Nanobiotechnology Introduction
11.5.4 Pfizer Revenue in Nanomedicine and Nanobiotechnology Business (2018-2023)
11.5.5 Pfizer Recent Development
11.6 CombiMatrix
11.6.1 CombiMatrix Company Detail
11.6.2 CombiMatrix Business Overview
11.6.3 CombiMatrix Nanomedicine and Nanobiotechnology Introduction
11.6.4 CombiMatrix Revenue in Nanomedicine and Nanobiotechnology Business (2018-2023)
11.6.5 CombiMatrix Recent Development
11.7 Celgene
11.7.1 Celgene Company Detail
11.7.2 Celgene Business Overview
11.7.3 Celgene Nanomedicine and Nanobiotechnology Introduction
11.7.4 Celgene Revenue in Nanomedicine and Nanobiotechnology Business (2018-2023)
11.7.5 Celgene Recent Development
11.8 Mallinckrodt
11.8.1 Mallinckrodt Company Detail
11.8.2 Mallinckrodt Business Overview
11.8.3 Mallinckrodt Nanomedicine and Nanobiotechnology Introduction
11.8.4 Mallinckrodt Revenue in Nanomedicine and Nanobiotechnology Business (2018-2023)
11.8.5 Mallinckrodt Recent Development
11.9 Sigma-Tau Pharmaceuticals
11.9.1 Sigma-Tau Pharmaceuticals Company Detail
11.9.2 Sigma-Tau Pharmaceuticals Business Overview
11.9.3 Sigma-Tau Pharmaceuticals Nanomedicine and Nanobiotechnology Introduction
11.9.4 Sigma-Tau Pharmaceuticals Revenue in Nanomedicine and Nanobiotechnology Business (2018-2023)
11.9.5 Sigma-Tau Pharmaceuticals Recent Development
11.10 Teva Pharmaceutical
11.10.1 Teva Pharmaceutical Company Detail
11.10.2 Teva Pharmaceutical Business Overview
11.10.3 Teva Pharmaceutical Nanomedicine and Nanobiotechnology Introduction
11.10.4 Teva Pharmaceutical Revenue in Nanomedicine and Nanobiotechnology Business (2018-2023)
11.10.5 Teva Pharmaceutical Recent Development
11.11 Nanosphere
11.11.1 Nanosphere Company Detail
11.11.2 Nanosphere Business Overview
11.11.3 Nanosphere Nanomedicine and Nanobiotechnology Introduction
11.11.4 Nanosphere Revenue in Nanomedicine and Nanobiotechnology Business (2018-2023)
11.11.5 Nanosphere Recent Development
11.12 UCB SA
11.12.1 UCB SA Company Detail
11.12.2 UCB SA Business Overview
11.12.3 UCB SA Nanomedicine and Nanobiotechnology Introduction
11.12.4 UCB SA Revenue in Nanomedicine and Nanobiotechnology Business (2018-2023)
11.12.5 UCB SA Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details